{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Suberoylanilide+hydroxamic+acid&page=3",
    "query": {
      "intervention": "Suberoylanilide hydroxamic acid",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 204,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Suberoylanilide+hydroxamic+acid&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Suberoylanilide+hydroxamic+acid&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T20:00:19.223Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01550224",
      "title": "Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With 11q23-abnormality in Relapse"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven E. Coutre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-05-01",
      "completion_date": "2014-11-17",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01550224"
    },
    {
      "nct_id": "NCT01059552",
      "title": "Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-12-16",
      "completion_date": "2019-10-21",
      "has_results": false,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Philadelphia, Pennsylvania • Charleston, South Carolina",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059552"
    },
    {
      "nct_id": "NCT00331955",
      "title": "Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-02",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331955"
    },
    {
      "nct_id": "NCT00818649",
      "title": "Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2009-01",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00818649"
    },
    {
      "nct_id": "NCT00831493",
      "title": "Vorinostat Plus Radiation Therapy in Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Chemoradiation (Radiation Therapy)",
          "type": "RADIATION"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2009-05",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2012-02-28",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831493"
    },
    {
      "nct_id": "NCT00787527",
      "title": "SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zolinza (vorinostat)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2008-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-09-09",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787527"
    },
    {
      "nct_id": "NCT01110876",
      "title": "Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-06",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110876"
    },
    {
      "nct_id": "NCT01728805",
      "title": "Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cutaneous T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "KW-0761",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2012-11",
      "completion_date": "2021-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728805"
    },
    {
      "nct_id": "NCT01193842",
      "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Plasmablastic Lymphoma",
        "AIDS-Related Primary Effusion Lymphoma",
        "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage I Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma",
        "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage III Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage IV Grade 3 Follicular Lymphoma",
        "HIV Infection",
        "Plasmablastic Lymphoma",
        "Primary Effusion Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2010-10-06",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2023-11-21",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 35,
      "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01193842"
    },
    {
      "nct_id": "NCT00336141",
      "title": "Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Suberoylanilide hydroxamic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2006-06",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2014-05-21",
      "last_synced_at": "2026-10-12T20:00:19.223Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336141"
    }
  ]
}